|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Verapamil#Adult Indications and Dosage]] |
| {{Verapamil}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==INDICATIONS AND USAGE==
| |
| | |
| Verapamil Hydrochloride Injection, USP is indicated for the following:
| |
| | |
| *Rapid conversion to sinus rhythm of [[PSVT|paroxysmal supraventricular tachycardias]], including those associated with accessory bypass tracts ([[Wolff-Parkinson-White]] [W-P-W] and [[Lown-Ganong- Levine]] [L-G-L] syndromes). When clinically advisable, appropriate [[vagal maneuvers ]](e.g., [[Valsalva maneuver]]) should be attempted prior to verapamil hydrochloride administration.
| |
| | |
| * Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the [[atrial flutter]] and/or [[atrial fibrillation]] are associated with accessory bypass tracts ([[Wolff-Parkinson-White]] (W-P-W) and Lown-Ganong-Levine (L-G-L) syndromes).
| |
| | |
| In controlled studies in the United States, about 60% of patients with [[supraventricular tachycardia]] converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of [[atrial flutter ]]or [[fibrillation]] to [[sinus rhythm]] is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection.
| |
| | |
| Because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole − see[[Verapamil hydrochloride injection contraindications|CONTRAINDICATIONS]] and [[Verapamil hydrochloride injection warnings|WARNINGS]]), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including D.C.-cardioversion capability (see [[Verapamil hydrochloride injection adverse reactions|ADVERSE REACTIONS]], Suggested Treatment of Acute Cardiovascular Adverse Reactions). As familiarity with the patient’s response is gained, use in an office setting may be acceptable.
| |
| [[Cardioversion ]]has been used safely and effectively after verapamil hydrochloride injection.
| |
| | |
| | |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VERAPAMIL HYDROCHLORIDE INJECTION, SOLUTION [CARDINAL HEALTH] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0c27c868-7eae-4b3e-babf-e89404ea27b7#nlm34090-1 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |